US 9,457,070

Application 13/209,349 · Granted Oct 4, 2016

Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease

Estimated expiration

June 7, 2026

Expired 168 days ago

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Jun 7, 2006
+ 20 years
Jun 7, 2026
PTA +404d
Jul 16, 2027
TD cap (US 9,884,096)
Jun 7, 2026
Final
Jun 7, 2026

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included. Terminal disclaimers can affect PTA (In re Cellect, LLC).

Calculation details

Base term

Filing date
August 12, 2011
Earliest effective filing
June 7, 2006
Issue date
October 4, 2016
PTA
+404 days
Base expiry (before PTA)
June 7, 2026

June 7, 2006 + 20 years = June 7, 2026 + 404 PTA days = July 16, 2027

  • Continuation-in-part of application 11/916,521, filed Dec 4, 2007
  • National stage entry of application PCTUS2006022436, filed Jun 7, 2006
  • National stage entry of application PCTUS2006022436, filed Jun 7, 2006
  • PRO60/687,850 — Provisional — not used for base term
  • PRO60/687,850 — Provisional — not used for base term
  • PRO60/687,850 — Provisional — not used for base term

Terminal disclaimers

TD approved2 approved, 2 filed

TD caps expiration to June 7, 2026 (earliest expiring referenced patent: US 9,884,096)

  • US 7,751,402

    Could not resolve calculation details

  • US 9,457,070· Application 13/209,349(from application 13/209,349)Capping patent

    Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease

    Filing date
    Aug 12, 2011
    Earliest effective filing
    Jun 7, 2006
    Issue date
    Oct 4, 2016
    PTA
    +404 days
    Calculated expiration
    Jul 16, 2027

    Continuation-in-part of 11/916,521, filed Dec 4, 2007

    National stage entry of PCTUS2006022436, filed Jun 7, 2006

    National stage entry of PCTUS2006022436, filed Jun 7, 2006

    Jun 7, 2006 + 20y + 404d PTA = Jul 16, 2027

  • US 9,884,096· Application 14/266,535(from application 14/266,535)Capping patent

    Compositions and methods related to graft versus host disease and treatments thereof

    Filing date
    Apr 30, 2014
    Earliest effective filing
    Jun 7, 2006
    Issue date
    Feb 6, 2018
    PTA
    0 days
    Calculated expiration
    Jun 7, 2026

    Continuation of 11/916,521, filed Dec 4, 2007

    National stage entry of PCTUS2006022436, filed Jun 7, 2006

    National stage entry of PCTUS2006022436, filed Jun 7, 2006

    Continuation of 14/063,986, filed Oct 25, 2013

    Continuation of 11/916,521, filed Dec 4, 2007

    Jun 7, 2006 + 20y = Jun 7, 2026

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 13/209,349 · US 9,457,070

PatentReply compiles the prosecution history behind US 9,457,070: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US9457070

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.